Jeff Yass’s Ovid Therapeutics OVID Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$243K Buy
97,700
+23,800
+32% +$62.3K ﹤0.01% 11472
2026
Q2
$199K Sell
73,900
-85,400
-54% -$220K ﹤0.01% 11958
2026
Q1
$354K Buy
159,300
+145,000
+1,014% +$259K ﹤0.01% 10502
2025
Q4
$23.3K Buy
+14,300
New +$22K ﹤0.01% 11926
2021
Q4
– Sell
-28,300
Closed -$95K – 13696
2021
Q3
$95K Buy
28,300
+5,900
+26% +$21.5K ﹤0.01% 12098
2021
Q2
$88K Sell
22,400
-120,200
-84% -$474K ﹤0.01% 12139
2021
Q1
$573K Buy
142,600
+10,100
+8% +$33.5K ﹤0.01% 9171
2020
Q4
$306K Buy
132,500
+100,400
+313% +$468K ﹤0.01% 9210
2020
Q3
$184K Buy
32,100
+7,800
+32% +$52.2K ﹤0.01% 9522
2020
Q2
$179K Buy
+24,300
New +$114K ﹤0.01% 9131

Other funds holding OVID

Jeff Yass's OVID Position: Q3 2026 in Review

Jeff Yass reduced its Ovid Therapeutics (OVID) stake by 59% in Q3 2026, selling an estimated $109K and leaving 28,913 shares worth $72K. The position accounts for ﹤0.01% of the portfolio, ranked #12739.

Jeff Yass first reported a position in OVID in Q4 2019 and has held it in 22 quarters since. The position peaked at $4.32M in Q1 2026. 123 funds tracked by Wall St. Rank hold OVID as of Q3 2026.

  • Jeff Yass held 28,913 shares of Ovid Therapeutics worth $72K as of Q3 2026.
  • Jeff Yass sold 41,687 Ovid Therapeutics shares in Q3 2026, an estimated $109K.
  • Ovid Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q3 2026, its #12739 holding.
  • Jeff Yass first reported a position in Ovid Therapeutics in Q4 2019 and has held it in 22 quarters since.
  • Jeff Yass's Ovid Therapeutics position peaked at $4.32M in Q1 2026.
  • 123 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q3 2026.

Based on Susquehanna International Group's 13F filing for Q3 2026, filed 16 Nov 2026.